Star Sports Medicine Co., Ltd. filed its inaugural monthly return to Hong Kong Exchanges and Clearing for the period ended 31 May 2026, confirming that both authorised and issued share capital remained unchanged after the company’s Main Board debut on 5 May 2026.

The registered and issued share capital closed the month at 54.83 million ordinary H shares with a par value of RMB 1 each, translating into total authorised capital of RMB 54.83 million. The filing shows no movements in authorised shares, issued shares or treasury shares during the month.

Public-float compliance was affirmed, with management certifying that the free-float ratio meets the Main Board’s initial prescribed threshold of 25% of issued shares.

The company reported no outstanding or newly granted share options, warrants, convertible securities or other equity-linked instruments, indicating a clean capital structure post-listing.

Joint Company Secretary Liang Xiaodan signed off that all listing-rule and statutory requirements were met and no additional securities transactions occurred in May.